Harvard's Stem Cell Insulin Breakthrough Gets Second Chance: Delhi HC Slams Patent Office Oversight

In a significant win for biotech innovation, the Delhi High Court has remanded Harvard University's patent application for lab-engineered pancreatic beta cells back to the Patent Office . Justice Tejas Karia ruled that the Controller committed a " glaring error " by ignoring amended claims submitted during hearings, setting aside the August 2022 refusal order. This procedural pivot could pave the way for patent grant on a potential diabetes therapy.

From Mouse Hosts to Man-Made Cells: The Quest for Better Beta Cells

Harvard College filed Patent Application No. 201617000758 in January 2016 , claiming "SC-β cells" – stem cell-derived pancreatic beta cells designed to mimic native ones but with enhanced traits like superior glucose-stimulated insulin secretion (GSIS). Unlike prior stem cell methods yielding immature cells needing months in mouse hosts, Harvard's invention promises in vitro maturation for drug testing and transplants.

The Controller rejected the application under Sections 3(j) (excluding plants/animals or parts thereof), 3(e) (mere admixture), and 10(4)/10(5) (insufficient description/definiteness). Timeline highlights: Priority from US applications ( 2013-14 ), PCT filing ( 2014 ), Indian entry ( 2016 ), First Examination Report ( 2020 ), hearings ( 2021 ), and refusal ( 2022 ). Harvard appealed under Section 117 of the Patents Act .

Harvard's Defense: Not Nature's Product, But Human Ingenuity

Harvard argued its non-native β cells – defined in the specification as lab-generated with distinct gene expression, crystalline insulin granules, key markers (INS, PDX1, NKX6-1, ZNT8), GSIS response, and mono-hormonal purity – transcend natural cells. They cited spec paras [193], [329], [511] detailing pharmaceutical compositions with carriers like saline or HBSS.

Key points: - Cells from stem cells (not always embryos) via technical protocols, not "essentially biological." - Amended claims shifted from "composition" (original Claim 1) to standalone " non-native pancreatic β cell ," addressing synergy objections. - Precedents like Imclone LLC v. Assistant Controller (engineered antibodies patentable) and BTS Research v. Controller (tri-hybrid cells outside Section 3(j)) support man-made cells. - Analogies to US Chakrabarty (engineered bacteria) and foreign grants in UK, US, etc. - Patent No. 404415 (stem cell composition) granted in India as comparable.

Patent Office Pushback: Just Isolated Natural Parts?

The Controller countered that SC-β cells, even cultured in vitro, are "plants/animals in whole or part" under Section 3(j), akin to Article 27.3(b) TRIPS . "Non-native" was vague without native benchmarks; cells from human stems are natural derivatives, not synthetic like microbes.

Respondent highlighted: - No genetic modification; spec admits non-genetically altered cells. - Myriad Genetics (isolated DNA unpatentable). - Indian policy excludes embryonic/human cell material; BTS distinguished as "wholly unnatural" fusions.

Harvard rejoined: Cells show altered profiles, better function; process is lab-directed, not biological.

Court's Razor-Sharp Focus: Amended Claims Demand Fresh Look

Justice Karia zeroed in on procedural flaw. The Impugned Order referenced but dismissed post-hearing amended claims as "alternative," basing rejection on originals. Comparing Claim 1 originals (composition with carriers) vs. amends (pure cell with traits), the shift alters patentability analysis under Sections 3(j) / 3(e) / 10(4)/10(5) .

Relying on Jitendra Kohli v. Controller ( "not considering amended claims is glaring error " ) and Akebia Therapeutics v. Controller (nature change from method to composition needs review), the Court held remand essential. No merits touched.

As reported in legal circles, " Delhi High Court directs re-examination of Harvard’s patent application on lab-engineered insulin cells," underscoring the " glaring error ."

Key Observations

"As the Impugned Order has only considered the original claims and not the amended claims filed along the post-hearing Written Submissions, it would be imperative to examine the impact of the amended claims on the Subject Application."

"In Jitendra Kohli v. The Controller of Patents ... 'The amended claims have not been taken into consideration by the Assistant Controller at the time of deciding the fate of Appellant's application. This is clearly a glaring error .'"

"Consequently, amended claims that significantly alter the original claims transitioning from a composition to a non-native pancreatic β cell must be duly considered by the learned Controller independently..."

Remand Roadmap: Six Months to Patent Clarity

The Court set aside the order, directing a fresh decision within six months by a different Controller, post-hearing. No influence from this judgment's observations. A copy goes to CGPDTM at llc-ipo@gov.in.

Implications : Reinforces that procedural lapses like ignoring amends void refusals. For biotech, it signals openness to re-evaluating Section 3(j) for engineered cells – a boon for diabetes research amid global grants. Future applicants: File amends boldly, but expect scrutiny on "non-native" vs. nature.